Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications


Clive Holmes, Ph.D., MRCPsych, Clinical Neurosciences Division, University of Southampton, Moorgreen Hospital, Botley Rd, Southampton, UK.
Tel.: 02380-475216;
Fax.: 02380-463022;


Clinical pharmaceutical trials aimed at modulating the immune system in Alzheimer's Disease have largely focused on either dampening down central proinflammatory innate immunity or have manipulated adaptive immunity to facilitate the removal of centrally deposited beta amyloid. To date, these trials have had mixed clinical therapeutic effects. However, a number of clinical studies have demonstrated disturbances of both systemic and central innate immunity in Alzheimer's Disease and attention has been drawn to the close communication pathways between central and systemic immunity. This paper highlights the need to take into account the potential systemic effects of drugs aimed at modulating central immunity and the possibility of developing novel therapeutic approaches based on the manipulation of systemic immunity and its communication with the central nervous system.